| BSCL2 / Seipin | |
|---|---|
| Protein Name | Berardinelli-Seip Congenital Lipodystrophy 2 Protein (Seipin) |
| Encoded by | [BSCL2](/entities/bscl2) |
| UniProt | [Q96G97](https://www.uniprot.org/uniprotkb/Q96G97/entry) |
| Localization | Endoplasmic reticulum membrane |
| Core Function | Lipid droplet biogenesis and ER lipid homeostasis |
| Neurologic Disease Link | Seipinopathy spectrum (dHMN, Silver syndrome, SPG17) |
BSCL2 (seipin) is an ER membrane protein required for normal lipid droplet formation and lipid partitioning.[1][2] Human disease data define two broad phenotypic classes: recessive loss-of-function states associated with congenital generalized lipodystrophy, and dominant missense seipinopathies (notably N88S/S90L) linked to motor-neuron-predominant neurodegeneration.[3][4]
Cryo-EM work resolved seipin as an oligomeric ring-like assembly that organizes neutral lipid phase transitions at ER-lipid droplet nucleation sites.[1:1][2:1] This architecture supports a scaffold-and-gate model:
Seipin dysfunction perturbs ER membrane organization, lipid droplet morphology, and stress signaling.
Although classically framed in adipocyte biology, seipin has direct neurologic relevance:
Experimental models indicate that seipin dysfunction can alter neuronal excitability and synaptic stability, consistent with motor-system vulnerability in BSCL2-related neurologic disorders.[5][6]
Dominant BSCL2 missense variants were first established in distal hereditary motor neuropathy and Silver syndrome, with broader phenotypic spread including SPG17-like presentations.[3:1][4:1]
Mechanistic themes include:
Seipinopathy is often modeled as a conformational disease: specific missense variants introduce toxic gain-of-function stress rather than simple haploinsufficiency.[5:2][7]
Seipin biology intersects with pathways central to ALS, hereditary spastic paraplegia, mitochondrial dysfunction, and ER stress, making BSCL2 a useful mechanistic bridge protein.
No approved disease-modifying therapy is specific for seipinopathy. Management remains supportive and phenotype-guided (neuromuscular rehabilitation, spasticity management, complication surveillance).
Potential strategies under study include:
An important translational constraint is mutation heterogeneity: interventions likely need genotype-specific logic (dominant toxic variants versus recessive loss-of-function contexts).
Sui X, et al. Cryo-electron microscopy structure of the lipid droplet-formation protein seipin. Journal of Cell Biology. 2018. ↩︎ ↩︎ ↩︎
Arlt H, et al. Seipin forms a flexible cage at lipid droplet formation sites. Nature Communications. 2022. ↩︎ ↩︎ ↩︎
Windpassinger C, et al. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nature Genetics. 2004. ↩︎ ↩︎
Irobi J, et al. The phenotype of motor neuropathies associated with BSCL2 mutations is broader than Silver syndrome and distal HMN type V. Brain. 2004. ↩︎ ↩︎
Ito D, et al. Molecular pathogenesis of seipin/BSCL2-related motor neuron diseases. Annals of Neurology. 2007. ↩︎ ↩︎ ↩︎
Guo Y, et al. Alleviation of seipinopathy-related ER stress by triglyceride storage. Human Molecular Genetics. 2013. ↩︎ ↩︎ ↩︎
Ito D, et al. Seipinopathy: a novel endoplasmic reticulum stress-associated disease. Brain. 2008. ↩︎ ↩︎